<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Evaluation of: Lange T, Hubmann M, Burkhardt R et al </plain></SENT>
<SENT sid="1" pm="."><plain>Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients after hematopoietic cell transplantation with reduced-intensity conditioning </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0001909'>Leukemia</z:hpo> 25, 498-505 (2011) </plain></SENT>
<SENT sid="3" pm="."><plain>Early detection of relapse is critical for patients who have undergone hematopoietic stem cell transplantation (HSCT) for <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) or high-grade <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), since therapy can be initiated while disease burden remains low </plain></SENT>
<SENT sid="4" pm="."><plain>As these <z:hpo ids='HP_0002664'>neoplasms</z:hpo> represent a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> group of <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> with distinct underlying mutations, no single genetic marker exists that both defines <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> and can be exploited for sensitive detection of neoplastic cells prior to overt hematologic relapse </plain></SENT>
<SENT sid="5" pm="."><plain>Conversely, the <z:e sem="disease" ids="C0027708" disease_type="Neoplastic Process" abbrv="">Wilms' tumor</z:e> gene (WT1) expression level is increased in blasts of most <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> patients, and quantitative analysis of WT1 expression has been used to predict relapse following myeloablative HSCT </plain></SENT>
<SENT sid="6" pm="."><plain>In this article, we review a recently published study evaluating the usefulness of multiple markers, including WT1 expression, for predicting relapse in <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> patients following reduced-intensity conditioning nonmyeloablative HSCT </plain></SENT>
</text></document>